- Home
- TXNM vs ICUI Comparison
TXNM vs ICUI Comparison
Compare TXNM & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXNM
- ICUI
- Stock Information
- Founded
- TXNM 1917
- ICUI 1984
- Country
- TXNM United States
- ICUI United States
- Employees
- TXNM N/A
- ICUI N/A
- Industry
- TXNM
- ICUI Medical/Dental Instruments
- Sector
- TXNM
- ICUI Health Care
- Exchange
- TXNM NYSE
- ICUI Nasdaq
- Market Cap
- TXNM 4.4B
- ICUI 3.6B
- IPO Year
- TXNM N/A
- ICUI 1992
- Fundamental
- Price
- TXNM $53.57
- ICUI $139.11
- Analyst Decision
- TXNM Buy
- ICUI Buy
- Analyst Count
- TXNM 7
- ICUI 4
- Target Price
- TXNM $53.57
- ICUI $199.67
- AVG Volume (30 Days)
- TXNM 1.4M
- ICUI 294.5K
- Earning Date
- TXNM 04-29-2025
- ICUI 05-06-2025
- Dividend Yield
- TXNM 3.04%
- ICUI N/A
- EPS Growth
- TXNM 162.37
- ICUI N/A
- EPS
- TXNM 2.67
- ICUI N/A
- Revenue
- TXNM $1,971,199,000.00
- ICUI $2,382,046,000.00
- Revenue This Year
- TXNM $14.45
- ICUI $0.21
- Revenue Next Year
- TXNM $4.92
- ICUI $2.47
- P/E Ratio
- TXNM $20.07
- ICUI N/A
- Revenue Growth
- TXNM 1.65
- ICUI 5.44
- 52 Week Low
- TXNM $35.35
- ICUI $93.36
- 52 Week High
- TXNM $55.50
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- TXNM 58.82
- ICUI 40.91
- Support Level
- TXNM $53.56
- ICUI $142.83
- Resistance Level
- TXNM $54.63
- ICUI $152.06
- Average True Range (ATR)
- TXNM 1.43
- ICUI 5.75
- MACD
- TXNM 0.04
- ICUI 0.51
- Stochastic Oscillator
- TXNM 62.08
- ICUI 52.59
About TXNM TXNM ENERGY INC
TXNM Energy Inc is a holding company that owns regulated utility companies providing energy to houses and businesses across Texas and New Mexico using its utilities.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.